Analysis of cytoskeleton-associated genes including RHOA, MYO9A, MYO9B, PXN, VCL, VASP, ACTβ, MYH9, as well as a selection of proto-oncogenic and tumour-suppressive targets related to drug anti-metastasis, such as BRAF, CDK4, EGFR, KEAP1, KRAS, PIK3CA, PTEN, PTPRD, TP5380–84 revealed no significant changes in expression levels, except for PXN, VASP, and KEAP1 (Fig. 7H–K). The gene discussed is KRAS; the disease is neoplasm.